Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes

JAMA, Journal Year: 2023, Volume and Issue: 330(6), P. 561 - 561

Published: July 14, 2023

This study examines the use of COVID-19 antiviral treatments in US nursing homes and facility characteristics associated with oral antivirals monoclonal antibodies.

Language: Английский

---

mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review

Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 27, 2024

Abstract Over the last 24 months, there has been growing evidence of a correlation between mRNA COVID-19 vaccine boosters and increased prevalence infection other pathologies. Recent works have added possible causation to correlation. may impair immune system response in compromised individuals. Multiple doses vaccines result much higher levels IgG 4 antibodies, or also impaired activation CD4 + CD8 T cells. The opportunity for needs careful consideration, as this impacts cost-to-benefit ratio boosters’ practice.

Language: Английский

---

Project NextGen: Developing the Next Generation of Coronavirus Disease 2019 (COVID-19) Vaccines and Therapeutics to Respond to the Present and Prepare for the Future

Clinical Infectious Diseases, Journal Year: 2024, Volume and Issue: 79(1), P. 115 - 121

Published: Feb. 13, 2024

Abstract Coronavirus disease 2019 (COVID-19) epidemiology and product landscapes have changed considerably since onset of the pandemic. Safe effective vaccines therapeutics are available, but continual emergence severe acute respiratory syndrome coronavirus 2 variants introduce limitations in our ability to prevent treat disease. Project NextGen is a collaboration between Biomedical Advanced Research Development Authority, part Administration for Strategic Preparedness Response, National Institute Allergy Infectious Diseases, Institutes Health, that leveraging public–private partnerships address gaps nation's COVID-19 vaccine therapeutic capabilities. Targeted investments will advance promising next-generation candidates through most difficult phases clinical development encourage further private sector interest later stage commercial availability. New more durable across improve fight against transform response future threats.

Language: Английский

---

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 176, P. 116900 - 116900

Published: June 10, 2024

Language: Английский

---

Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(7), P. e0304822 - e0304822

Published: July 16, 2024

To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness sotrovimab versus no treatment in preventing severe clinical outcomes.

Language: Английский

---

Cost-effectiveness of preventive COVID-19 interventions: a systematic review and network meta-analysis of comparative economic evaluation studies based on real-world data

Journal of Global Health, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 20, 2025

There is a knowledge gap regarding the effectiveness and utility of various preventive interventions during COVID-19 pandemic. In this study, we aimed to evaluate cost-effectiveness interventions, including non-medical (NMIs) vaccination programs, using real-world data across different demographic socioeconomic contexts worldwide. We searched Medline, Cochrane Library, Embase, Web Science Core Collection from December 2019 March 2024. identified 75 studies which compared 34 interventions. conducted network meta-analysis assess incremental net benefits (INB) these both societal health care system perspectives. adjusted purchasing power parity (PPP) standardised willingness pay (WTP) enhance comparability economic levels. performed sensitivity subgroup analyses examine robustness results. Movement restrictions expanding testing emerged as most cost-effective strategies perspective, with WTP-standardised INB values USD 21 050 11 144. contrast, combinations NMIs were less cost-effective, particularly in high-income regions. From plus distancing test, trace, isolate strategy highly while masking requirements economically viable. The varied significantly contexts, underlining necessity for region-specific strategies. highlight significant variations Tailoring specific regional infrastructural conditions crucial. Continuous evaluation adaptation are essential effective management ongoing future public threats. PROSPERO: CRD42023385169.

Language: Английский

---

Predicting pathogen evolution and immune evasion in the age of artificial intelligence

Computational and Structural Biotechnology Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

The genomic diversification of viral pathogens during epidemics and pandemics represents a major adaptive route for infectious agents to circumvent therapeutic public health initiatives. Historically, strategies address evolution have relied on responding emerging variants after their detection, leading delays in effective responses. Because this, long-standing yet challenging objective has been forecast by predicting potentially harmful mutations prior emergence. promises artificial intelligence (AI) coupled with the exponential growth data collection infrastructures spurred COVID-19 pandemic, resulted research ecosystem highly conducive this objective. Due pandemic accelerating development mitigation preparedness strategies, many methods discussed here were designed context SARS-CoV-2 evolution. However, most these pipelines intentionally be adaptable across RNA viruses, several already applied multiple species. In review, we explore recent breakthroughs that facilitated forecasting an ongoing particular emphasis deep learning architectures, including promising potential language models (LM). approaches employ leverage genomic, epidemiologic, immunologic biological information.

Language: Английский

---

Advancing Health Equity for American Indian and Alaska Native People Through Inclusion in Clinical Trials: Anti-SARS-CoV-2 Monoclonal Antibody Treatment and COVID-19 Outcomes Among Ambulatory Cherokee Nation Health Services Patients

Health Equity, Journal Year: 2025, Volume and Issue: 9(1), P. 235 - 244

Published: Feb. 1, 2025

Language: Английский

---

Is LDL cholesterol associated with long-term mortality among primary prevention adults? A retrospective cohort study from a large healthcare system

BMJ Open, Journal Year: 2024, Volume and Issue: 14(3), P. e077949 - e077949

Published: March 1, 2024

Objectives Among primary prevention-type adults not on lipid-lowering therapy, conflicting results exist the relationship between low-density lipoprotein cholesterol (LDL-C) and long-term mortality. We evaluated this in a real-world evidence population of adults. Design Retrospective cohort study. Setting Electronic medical record data for adults, from 4 January 2000 through 31 December 2022, were extracted University Pittsburgh Medical Center healthcare system. Participants Adults without diabetes aged 50–89 years statin therapy at baseline or within 1 year classified as patients. To mitigate potential reverse causation, patients who died had total (T-C) ≤120 mg/dL LDL-C <30 excluded. Main exposure measure Baseline categories 30–79, 80–99, 100–129, 130–159, 160–189 ≥190 mg/dL. outcome All-cause mortality with follow-up starting 365 days after measurement. Results 177 860 mean (SD) age 61.1 (8.8) 119 (31) over 6.1 follow-up. A U-shaped was observed six crude 10-year rates 19.8%, 14.7%, 11.7%, 10.7%, 10.1% 14.0%, respectively. Adjusted HRs compared referent group 80–99 were: 30–79 (HR 1.23, 95% CI 1.17 to 1.30), 100–129 (0.87, 0.83–0.91), 130–159 (0.88, 0.84–0.93), (0.91, 0.84–0.98) (1.19, 1.06–1.34), Unlike LDL-C, both T-C/HDL (high-density cholesterol) triglycerides/HDL ratios independently associated Conclusions lowest risk appears wide range 100–189 mg/dL, which is much higher than current recommendations. For counselling these patients, minimal consideration should be given concentration.

Language: Английский

---

Phase II Study of Bemnifosbuvir in High-Risk Participants in a Hospital Setting with Moderate COVID-19

Future Virology, Journal Year: 2023, Volume and Issue: 18(8), P. 489 - 500

Published: June 1, 2023

Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro.Adults hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysis; part B enrollment limited owing evolving standard of care.Although the study ended early and did not meet primary efficacy end point, bemnifosbuvir was well tolerated contribute all-cause mortality. Compared placebo, treatment resulted 0.61 log10 greater viral load mean change on day 2; trend sustained through 8. Treatment-emergent adverse events similar both groups; most mild/moderate, unrelated drug.Our results suggest potential role for blunting progression.NCT04396106 (ClinicalTrials.gov).

Language: Английский

---